Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | FNTA | P49354 | 7/20 | 0.47 |
| ▸ | FNTB | P49356 | 7/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FPR1 | P21462 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL7222094 | 1.00 | LTA4H (0.50) | LTA4HFNTAFNTBPGGT1BALPI | |
| Dl-Phenylalanine SCHEMBL21722624 | 0.90 | FPR1 (0.55) | LTA4HFNTAFNTBPGGT1BFPR1 | |
| Phenylalanine SCHEMBL3455844 | 0.90 | FPR1 (0.55) | LTA4HFNTAFNTBPGGT1BFPR1 | |
| SCHEMBL856024 | 0.89 | FNTA (0.54) | LTA4HFNTAFNTBPGGT1BFPR1 | |
| SCHEMBL18106731 | 0.89 | FNTA (0.54) | LTA4HFNTAFNTBPGGT1BFPR1 | |
| Leucine SCHEMBL1393748 | 0.88 | SLC7A5 (0.50) | FNTAFNTBPGGT1BSLC7A5FPR1 | |
| Phenylalanine SCHEMBL907512 | 0.85 | SLC7A5 (0.58) | LTA4HFNTAFNTBPGGT1BALPI | |
| D-Phenylalanine SCHEMBL6450960 | 0.85 | SLC7A5 (0.58) | LTA4HFNTAFNTBPGGT1BALPI | |
| Phenylalanine SCHEMBL7263675 | 0.83 | FPR1 (0.51) | FNTAFNTBPGGT1BFPR1FPR2 | |
| SCHEMBL61200 | 0.82 | ANPEP (0.43) | LTA4HFNTAFNTBPGGT1BFPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2573569-A1 | Antibodies, compositions, and assays for detection of cardiac disease | Nour Heart, Inc. (US) | 2013-03-27 | — | — | EP | claimed |
| US-8377685-B2 | Microfluidic device having stable static gradient for analyzing chemotaxis | BELLBROOK LABS, LLC (US) | 2013-02-19 | — | — | US | claimed |
| US-20120216303-A1 | NOVEL THERAPEUTIC USES OF HUMAN FORMYL PEPTIDE RECEPTOR ANTAGONISTS | NIKAN PHARMACEUTICALS, LLC (US) | 2012-08-23 | — | — | US | claimed |
| EP-2214828-A1 | MICROFLUIDIC DEVICE HAVING STABLE STATIC GRADIENT FOR ANALYZING CHEMOTAXIS | Bellbrook Labs, Llc (US) | 2010-08-11 | — | — | EP | claimed |
| US-20090123961-A1 | MICROFLUIDIC DEVICE HAVING STABLE STATIC GRADIENT FOR ANALYZING CHEMOTAXIS | BELLBROOK LABS, LLC | 2009-05-14 | — | — | US | claimed |
| WO-2009062095-A1 | MICROFLUIDIC DEVICE HAVING STABLE STATIC GRADIENT FOR ANALYZING CHEMOTAXIS | BELLBROOK LABS, LLC (US) | 2009-05-14 | — | — | WO | claimed |
| US-20080260650-A1 | Methods of Detection and Therapy of Inflamed Tissues Using Immune Modulation | THE GENERAL HOSPITAL CORPORATION (US) | 2008-10-23 | — | — | US | claimed |
| US-20080193376-A1 | Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation | THE GENERAL HOSPITAL CORPORATION (US) | 2008-08-14 | — | — | US | claimed |
| WO-2006049599-A1 | METHODS OF DETECTION AND THERAPY FOR ATHEROMATOUS PLAQUES USING IMMUNE MODULATION | THE GENERAL HOSPITAL CORPORATION (US) | 2006-05-11 | — | — | WO | claimed |
| WO-2006050058-A2 | METHODS OF DETECTION AND THERAPY OF INFLAMED TISSUES USING IMMUNE MODULATION | THE GENERAL HOSPITAL CORPORATION (US) | 2006-05-11 | — | — | WO | claimed |
| US-20040261140-A1 | Transgenic mice expressing human formyl peptide receptor | NIKAN PHARMACEUTICALS, LLC | 2004-12-23 | — | — | US | claimed |
| US-6699905-B2 | COMPRISING ADMINISTERING TO THE SUBJECT AN EFFECTIVE ANTI-INFLAMMATORY AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING A LIPOXIN A4 COMPOUND AND A PHARMACEUTICALLY ACCEPTABLE CARRIER | BRIGHAM AND WOMEN'S HOSPITAL | 2004-03-02 | — | — | US | claimed |
| US-20030060512-A1 | Modulation of inflammation related to columnar epithelia | MADARA JAMES L (US) | 2003-03-27 | — | — | US | claimed |
| US-20020045579-A1 | Modulation of inflammation related to columnar epithelia | MADARA JAMES L (US) | 2002-04-18 | — | — | US | claimed |
| US-4970162-A | Human-mouse hybrid cell line expressing monocyte-macrophage properties | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1990-11-13 | — | — | US | claimed |
| EP-4710935-A2 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | Aravax Pty Ltd (AU) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024128630-A1 | BLOOD PERFUSION DEVICE FOR REDUCING SECONDARY NOSOCOMIAL INFECTIONS IN HOSPITAL | 서울대학교산학협력단 | 2024-06-20 | — | — | WO | disclosed |
| US-4986979-A | Imaging tissue sites of inflammation | NEORX CORPORATION | 1991-01-22 | — | — | US | disclosed |
| US-4970162-A | Human-mouse hybrid cell line expressing monocyte-macrophage properties | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1990-11-13 | — | — | US | disclosed |
| US-4970162-A | Human-mouse hybrid cell line expressing monocyte-macrophage properties | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1990-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060512-A1 | Modulation of inflammation related to columnar epithelia | LTB4R2, ALOX15B, LTB4R | LTA4H 10/4885FNTA 1165/4885FNTB 1729/4885 |
| US-20020045579-A1 | Modulation of inflammation related to columnar epithelia | LTB4R2, ALOX15B, LTB4R | LTA4H 10/4885FNTA 1165/4885FNTB 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.